Structured abstract for full paper Background After recovery from COVID-19, most patients
have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an …

In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care
to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS …

Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …

Background Passive immunotherapy with convalescent plasma (CP) is a potential treatment
for COVID-19 for which evidence from controlled clinical trials is lacking. Methods We …

Convalescent plasma is a suggested treatment for Coronavirus disease 2019 (Covid-19),
but its efficacy is uncertain. We aimed to evaluate whether the use of convalescent plasma is …

Background Early administration of convalescent plasma obtained from blood donors who
have recovered from coronavirus disease 2019 (Covid-19) may prevent disease …

Background Convalescent plasma is frequently administered to patients with Covid-19 and
has been reported, largely on the basis of observational data, to improve clinical outcomes …

Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

Background The effects of convalescent plasma (CP) therapy in hospitalised patients with
coronavirus disease 2019 (COVID-19) remain uncertain. This study investigates the effect of …